Tesamorelin

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH), not growth hormone itself. It stimulates the pituitary gland to produce and release your body's own GH in a pulsatile, physiological manner. This is different from exogenous GH administration, which provides a constant level of GH and bypasses the body's natural regulatory mechanisms.

Yes, tesamorelin was FDA approved in 2010 under the brand name Egrifta for the treatment of HIV-associated lipodystrophy (excess abdominal fat in HIV patients). Our research-grade tesamorelin is for in vitro research purposes only and is not intended for human use.

Phase III clinical trials demonstrated that tesamorelin reduced visceral adipose tissue by approximately 15-18% over 26-52 weeks of treatment in HIV patients with lipodystrophy. Importantly, research showed it selectively targeted visceral fat while preserving lean body mass and subcutaneous fat levels.

Recent research has explored tesamorelin's effects on brain structure and cognitive function, particularly in older adults with mild cognitive impairment. Studies have reported changes in regional brain volume and some measures of executive function, potentially mediated through increased IGF-1 crossing the blood-brain barrier.

Clinical trials reported injection site reactions as the most common adverse event. As a GH secretagogue, it can affect glucose metabolism and is contraindicated in patients with active malignancy. Long-term safety data from the FDA approval process is available in the prescribing information for Egrifta.

Lyophilized (freeze-dried) tesamorelin should be stored at -20°C for long-term stability. Once reconstituted with bacteriostatic water, it should be refrigerated at 2-8°C and used within 14 days. Avoid repeated freeze-thaw cycles and protect from light.